Skip to main content
Terug
TLX logo

Telix Pharmaceuticals Limited

Datakwaliteit: 100%
TLX
NASDAQ Healthcare Biotechnology
€ 8,90
▲ € 0,13 (1,48%)
Marktkapitalisatie: 3,02B
Ook genoteerd als TLPPF OTC
Dagbereik
€ 8,87 € 9,01
52-Weeksbereik
€ 6,28 € 20,00
Volume
119.227
50D / 200D Gem.
€ 7,42 / € 10,51
Vorige Slotkoers
€ 8,77

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -282,2 0,3
P/B 4,9 3,0
ROE % -1,8 3,7
Net Margin % -0,9 3,8
Rev Growth 5Y % 254,9 10,0
D/E 1,3 0,2

Koersdoel Analisten

Hold
€ 17,00 +91.0%
Forward K/W
179,80
Forward WPA
€ 0,05
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,37B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,07
€ 1,01 – € 1,16
 2,36B 3
FY2029 € 0,79
€ 0,75 – € 0,86
 1,95B 3
FY2028 € 0,39
-€ 0,18 – € 0,78
 1,81B 9

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-19 -€ 0,12 -€ 0,01 +87,9%
2025-08-20 € 0,13 -€ 0,01 -105,1%
2025-02-20 € 0,09 € 0,07 -25,2%
2024-08-22 € 0,09 € 0,02 -75,0%
2023-12-31 N/A € 0,04 —
2023-06-30 € 0,04 -€ 0,03 -179,9%
2022-12-31 -€ 0,05 -€ 0,07 -45,6%
2022-06-30 -€ 0,08 -€ 0,16 -92,7%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 254,93% annually over 5 years — strong growth
Earnings declined -121,40% over the past year
Negative free cash flow of -82,80M
Revenue growth is decelerating — 1Y growth trails 5Y average by 201,02%
Capital efficient — spends only 4,72% of revenue on capex
ROIC of 1,42% — low return on invested capital

Groei

Revenue Growth (5Y)
254,93%
Revenue (1Y)53,91%
Earnings (1Y)-121,40%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-1,80%
ROIC1,42%
Net Margin-0,89%
Op. Margin2,21%

Veiligheid

Debt / Equity
1,26
Current Ratio1,43
Interest Coverage0,48

Waardering

P/E Ratio
-282,18
Forward P/E184,44
P/B Ratio4,85
EV/EBITDA134,64
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 53,91% Revenue Growth (3Y) 54,88%
Earnings Growth (1Y) -121,40% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 254,93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,21B Net Income (TTM) -10,69M
ROE -1,80% ROA -0,60%
Gross Margin 53,11% Operating Margin 2,21%
Net Margin -0,89% Free Cash Flow (TTM) -82,80M
ROIC 1,42% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,26 Current Ratio 1,43
Interest Coverage 0,48
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -282,18 Forward P/E 184,44
P/B Ratio 4,85 P/S Ratio 2,50
PEG Ratio 2,93 Forward PEG N/A
EV/EBITDA 134,64 Fwd EV/EBITDA N/A
Forward P/S 2,20 Fwd Earnings Yield 0,54%
FCF Yield -2,75%
Market Cap 3,02B Enterprise Value 3,59B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,21B 783,21M 502,55M 160,10M 7,60M
Net Income -10,69M 49,92M 5,21M -104,08M -80,51M
EPS (Diluted) -0,03 0,14 0,02 -0,34 -0,29
Gross Profit 640,23M 509,68M 314,39M 29,34M -29,77M
Operating Income 26,64M 82,13M 51,89M -91,93M -81,25M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,77B 1,52B 398,30M 260,59M 109,81M
Total Liabilities 1,15B 948,22M 249,39M 175,35M 106,17M
Shareholders' Equity 622,27M 568,21M 148,91M 80,01M 2,16M
Total Debt 784,47M 581,45M 17,45M 10,45M 2,54M
Cash & Equivalents 212,53M 710,35M 123,24M 116,33M 22,04M
Current Assets 494,79M 918,56M 224,85M 173,23M 47,54M
Current Liabilities 347,00M 330,91M 157,41M 85,56M 37,98M